Archived explainer. For the current picture see today's DYN page.
Why Is DYNE THERAPEUTICS IN (DYN) Stock Down Today?
By the Top Tier Newswire AI Desk · September 10, 2026 at 10:05 AM ET · reviewed against 8 wire stories
DYNE THERAPEUTICS IN (DYN) is down -6.10% in the latest session. Our newswire has captured 8 stories on DYN across 5 sources in the last 36 hours, with AI sentiment reading bearish (avg 38/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why DYN stock is down today
Dyne Therapeutics (DYN) fell 6.10% to $18.02 in afternoon trading, extending a broader decline that has seen the stock drop 22.7% over the past eight sessions. The move follows a series of downgraded analyst price targets and a broader market reassessment of the company’s prospects in light of a recent Phase 3 trial failure by Novartis in the same therapeutic area.
What Happened
RBC Capital, Morgan Stanley, and Baird all reduced their price targets for DYN in the last 36 hours, citing concerns over the competitive landscape and the impact of Novartis’ setback. RBC cut its target to $30 from $35, while Morgan Stanley lowered its target to $36 from $45 and Baird to $26 from $30. These moves reflect a reassessment of Dyne’s lead asset, z-rostudirsen, and its differentiation from Novartis’ drug. Analysts highlighted differences in drug design and clinical trial approaches but noted that the broader market has reacted cautiously. J.P. Morgan also downgraded the stock, citing the Novartis trial failure as a negative signal for the class of drugs Dyne is developing.
What The Data Shows
The stock opened at $19.20 and has since fallen to $17.99, with a session low of $17.93. Trading volume is at 0.5 million shares, which is 0.3 times the 3-month average. Over the past 30 days, sentiment has deteriorated from an average of 42 out of 100 to 38. In the last 90 days, insiders have sold 18 times, totaling $113.8 million. The stock hit a new 52-week low on September 10 and has printed 14 fresh 52-week lows that day. Unusual options activity included two notable prints, with $10.7 million in call premium traded.
What To Watch
With no immediate catalysts confirmed and a bearish trend in analyst ratings and insider sales, investors should monitor the stock for further guidance or updates on clinical progress. The next key event will be Dyne’s quarterly earnings report, if scheduled.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
DYN · Sep 10 session (5-min) · -6.94% vs prior close · updated 8:48 PM ETAI sentiment, last 36h · averaged over 8 stories · 38/100 bearish
The headlines behind the move
Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoStocktwits NewsBEARISH 38General
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
RBC Capital highlighted differences in how Novartis’ and Dyne’s drugs target transferrin protein, their payloads, and their clinical trial designs.
3d agoSeeking AlphaBEARISH 34Analyst
Dyne extends slide as J.P. Morgan downgrades on Novartis setback
Dyne Therapeutics (DYN) stock extends its decline as J.P. Morgan downgrades the firm, citing impact from a trial setback for a Novartis (NVS) medicine. Read more here.
3d agoInvesting.com Analyst RatingsBEARISH 34Analyst
Dyne Therapeutics stock price target lowered to $30 by RBC Capital
Dyne Therapeutics stock price target lowered to $30 by RBC Capital
3d agoThe FlyBEARISH 34Analyst
Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley
3d agoThe FlyBEARISH 34Analyst
Dyne Therapeutics price target lowered to $30 from $35 at RBC Capital
4d agoSeeking AlphaBULLISH 58Analyst
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Dyne Therapeutics lead asset z-rostudirsen faces regulatory and confirmatory risks, with FDA approval likely. Find out why DYN stock is a buy.
4d agoThe FlyBEARISH 38Analyst
Dyne Therapeutics price target lowered to $26 from $30 at Baird
5d agoYahoo TopBEARISH 34General
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed
Dyne Therapeutics shares fell 31% to $16.76 in premarket trading, with no company-specific clinical, regulatory or financial catalyst confirmed.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →